SEC Form 4 · accession 0001140361-16-090132

AVADEL PHARMACEUTICALS PLC · AVDL

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — See Remarks

Period of report

Dec 14, 2016

Accepted (ET)

Dec 16, 2016 · 9:05 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001012477

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
ADSs^F1,F2	Dec 14, 2016	A	2,000	—	A	2,000	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F4	$10.40	Dec 14, 2016	A	14,000	A	—	Dec 14, 2016	ADSs	14,000	14,000	D
Stock Option (right to buy)^F3	$7.85	holding	—	—	—	—	Mar 2, 2026	ADSs	50,000	50,000	D

F1The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts. The securities acquired as reported in this statement represent the grant of ADSs under the issuer's "Free Share" award program; no purchase price was applicable to such grant. See footnote (2) for details as to the dates such ADSs will be issued to the reporting person.
F2Represents 2,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the second anniversary of the grant date.
F3Options become exercisable as to 12,500 ADSs on each of the first four anniversaries after the 03/02/2016 grant date.
F4Options become exercisable as to 3,500 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.

Controller & CAO